Group 1 - The core viewpoint of the news is that Suzhou Haofan Biological Co., Ltd. (昊帆生物) has shown significant revenue growth in its latest quarterly report, indicating a positive financial performance despite a recent decline in stock price [1][3] - As of August 1, 2025, the company's stock closed at 59.05 yuan, down 4.28%, with a trading volume of 5.91 million shares and a transaction amount of 362 million yuan [1] - The company reported total revenue of 135 million yuan for the first quarter of 2025, representing a year-on-year growth of 48.21%, and a net profit attributable to shareholders of 34.79 million yuan, up 16.66% year-on-year [1] Group 2 - The company has a current liquidity ratio of 28.624 and a quick ratio of 26.963, indicating strong short-term financial health [1] - The debt-to-asset ratio stands at 3.40%, suggesting low leverage and financial risk [1] - Haofan Biological has made investments in 6 companies and participated in 9 bidding projects, showcasing its active engagement in business expansion [2]
昊帆生物（301393）8月1日主力资金净流出1608.35万元